{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:39:46Z","timestamp":1793176786537,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI21C0977"],"award-info":[{"award-number":["HI21C0977"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.clgc.2023.11.003","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T14:09:24Z","timestamp":1699625364000},"page":"224-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective"],"prefix":"10.1016","volume":"22","author":[{"given":"Ji Min","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euno","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Hee","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9322-7540","authenticated-orcid":false,"given":"Jungmin","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghui","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.11.003_bib0001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2023.11.003_bib0002","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0003","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.3390\/cancers14102545","article-title":"Immune checkpoint inhibitors as a neoadjuvant\/adjuvant treatment of muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Barone","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2023.11.003_bib0004","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0007","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clgc.2023.11.003_bib0008","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0009","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2023.11.003_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.678896","article-title":"Curative effect and survival assessment comparing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant therapy for bladder cancer: a systematic review and meta-analysis","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0011","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1001\/jamaoncol.2018.3542","article-title":"Downstaging and survival outcomes associated with neoadjuvant chemotherapy regimens among patients treated with cystectomy for muscle-invasive bladder cancer","volume":"4","author":"Peyton","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0012","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.3390\/cancers13112770","article-title":"Comparison of oncologic outcomes of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy for muscle-invasive bladder cancer: systematic review and meta-analysis","volume":"13","author":"Chung","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2023.11.003_bib0013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euf.2019.10.017","article-title":"Neoadjuvant therapies for bladder cancer in cisplatin-ineligible patients: what options do we have?","volume":"6","author":"Basu","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2023.11.003_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.euf.2019.10.016","article-title":"Predicting response to neoadjuvant chemotherapy in bladder cancer","volume":"6","author":"Motterle","year":"2020","journal-title":"Eur Urol focus"},{"key":"10.1016\/j.clgc.2023.11.003_bib0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3390\/cancers14010038","article-title":"Bladder-sparing chemoradiotherapy combined with immune checkpoint inhibition for locally advanced urothelial bladder cancer: a review","volume":"14","author":"van Hattum","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clgc.2023.11.003_bib0016","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multistakeholder effort(\u2020): under the auspices of the EAU-ESMO guidelines committees","volume":"77","author":"Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0017","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12894-020-00733-z","article-title":"Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients","volume":"20","author":"Hamid","year":"2020","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.euf.2019.08.009","article-title":"Clinical complete response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a call for standardized assessments and definitions","volume":"6","author":"Winoker","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.clgc.2023.11.003_bib0019","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.clgc.2023.11.003_bib0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/01.ju.0000090967.08622.33","article-title":"Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis","volume":"171","author":"Winquist","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0021","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration","volume":"48","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0022","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s12094-022-02815-w","article-title":"SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021)","volume":"24","author":"Valderrama","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0023","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2023.11.003_bib0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2020.10.006","article-title":"Systemic therapy in bladder preservation","volume":"41","author":"Girardi","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0026","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1002\/cncr.11232","article-title":"Can patient selection for bladder preservation be based on response to chemotherapy?","volume":"97","author":"Sternberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2090598X.2021.1994230","article-title":"The effect of neoadjuvant chemotherapy among patients undergoing radical cystectomy for variant histology bladder cancer: a systematic review","volume":"20","author":"Alvarez-Maestro","year":"2022","journal-title":"Arab J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0028","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clgc.2015.09.013","article-title":"Predictors of complete pathologic response (pT0) to neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"14","author":"Pokuri","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0029","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.path.2022.08.003","article-title":"Urothelial carcinoma: update on staging and reporting, and pathologic changes following neoadjuvant chemotherapies","volume":"15","author":"Aron","year":"2022","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.clgc.2023.11.003_bib0030","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0031","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.clgc.2020.10.002","article-title":"Response to neoadjuvant chemotherapy and survival in micropapillary urothelial carcinoma: data from a tertiary referral center and the surveillance, epidemiology, and end results (SEER) program","volume":"19","author":"Diamantopoulos","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0032","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-190258","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0033","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0034","doi-asserted-by":"crossref","first-page":"108.e101","DOI":"10.1016\/j.urolonc.2021.09.017","article-title":"Plasmacytoid urothelial carcinoma of the bladder: MRI features and their association with survival","volume":"40","author":"Woo","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0035","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1007\/s00261-021-02963-7","article-title":"Diagnostic performance of contrast-enhanced dynamic and diffusion-weighted MR imaging in the assessment of tumor response to neoadjuvant therapy in muscle-invasive bladder cancer","volume":"46","author":"Ahmed","year":"2021","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.clgc.2023.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/PAS.0b013e3181ec86b3","article-title":"Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists","volume":"34","author":"Sangoi","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0037","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.humpath.2019.04.012","article-title":"Plasmacytoid\/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients","volume":"90","author":"Perrino","year":"2019","journal-title":"Hum Pathol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.clgc.2023.11.003_bib0039","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/PAS.0000000000000142","article-title":"Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival","volume":"38","author":"Fleischmann","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0040","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1186\/s12885-021-08840-2","article-title":"Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial","volume":"21","author":"Hinsenveld","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0041","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.4143\/crt.2020.1356","article-title":"Neoadjuvant chemotherapy-guided bladder-sparing treatment for muscle-invasive bladder cancer: results of a pilot phase II study","volume":"53","author":"Shi","year":"2021","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.clgc.2023.11.003_bib0042","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0043","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.juro.2015.10.133","article-title":"Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer-does pT0 predict better survival than pTa\/Tis\/T1?","volume":"195","author":"Zargar","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0044","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/PAS.0000000000001371","article-title":"Multicenter validation of histopathologic tumor regression grade after neoadjuvant chemotherapy in muscle-invasive bladder carcinoma","volume":"43","author":"Voskuilen","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0045","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.juro.2012.10.120","article-title":"Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer","volume":"189","author":"Yuh","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.11.003_bib0046","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.urology.2014.03.040","article-title":"The utility of an extensive postchemotherapy staging evaluation in patients receiving neoadjuvant chemotherapy for bladder cancer","volume":"84","author":"Reese","year":"2014","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2023.11.003_bib0047","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clgc.2015.08.006","article-title":"Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation","volume":"14","author":"Zargar-Shoshtari","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0048","doi-asserted-by":"crossref","first-page":"e1063","DOI":"10.1016\/j.clgc.2017.07.008","article-title":"Squamous differentiation predicts poor response to cisplatin-based chemotherapy and unfavorable prognosis in urothelial carcinoma of the urinary bladder","volume":"15","author":"Minato","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2023.11.003_bib0049","doi-asserted-by":"crossref","first-page":"E325","DOI":"10.1111\/j.1464-410X.2012.11751.x","article-title":"Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer","volume":"111","author":"Meeks","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2023.11.003_bib0050","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.urology.2009.06.111","article-title":"Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer","volume":"75","author":"Yoshida","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2023.11.003_bib0051","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"European urology focus"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323002409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:27:39Z","timestamp":1793176059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323002409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1558767323002409"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.11.003","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}